These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

718 related articles for article (PubMed ID: 14519709)

  • 1. Azithromycin in patients with cystic fibrosis chronically infected with Pseudomonas aeruginosa: a randomized controlled trial.
    Saiman L; Marshall BC; Mayer-Hamblett N; Burns JL; Quittner AL; Cibene DA; Coquillette S; Fieberg AY; Accurso FJ; Campbell PW;
    JAMA; 2003 Oct; 290(13):1749-56. PubMed ID: 14519709
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of azithromycin on pulmonary function in patients with cystic fibrosis uninfected with Pseudomonas aeruginosa: a randomized controlled trial.
    Saiman L; Anstead M; Mayer-Hamblett N; Lands LC; Kloster M; Hocevar-Trnka J; Goss CH; Rose LM; Burns JL; Marshall BC; Ratjen F;
    JAMA; 2010 May; 303(17):1707-15. PubMed ID: 20442386
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Long term effects of azithromycin in patients with cystic fibrosis: A double blind, placebo controlled trial.
    Clement A; Tamalet A; Leroux E; Ravilly S; Fauroux B; Jais JP
    Thorax; 2006 Oct; 61(10):895-902. PubMed ID: 16809416
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Heterogeneity of treatment response to azithromycin in patients with cystic fibrosis.
    Saiman L; Mayer-Hamblett N; Campbell P; Marshall BC;
    Am J Respir Crit Care Med; 2005 Oct; 172(8):1008-12. PubMed ID: 16040785
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Open-label, follow-on study of azithromycin in pediatric patients with CF uninfected with Pseudomonas aeruginosa.
    Saiman L; Mayer-Hamblett N; Anstead M; Lands LC; Kloster M; Goss CH; Rose LM; Burns JL; Marshall BC; Ratjen F;
    Pediatr Pulmonol; 2012 Jul; 47(7):641-8. PubMed ID: 22684984
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of azithromycin maintenance treatment on infectious exacerbations among patients with non-cystic fibrosis bronchiectasis: the BAT randomized controlled trial.
    Altenburg J; de Graaff CS; Stienstra Y; Sloos JH; van Haren EH; Koppers RJ; van der Werf TS; Boersma WG
    JAMA; 2013 Mar; 309(12):1251-9. PubMed ID: 23532241
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A formulation of aerosolized tobramycin (Bramitob) in the treatment of patients with cystic fibrosis and Pseudomonas aeruginosa infection: a double-blind, placebo-controlled, multicenter study.
    Chuchalin A; Csiszér E; Gyurkovics K; Bartnicka MT; Sands D; Kapranov N; Varoli G; Monici Preti PA; Mazurek H
    Paediatr Drugs; 2007; 9 Suppl 1():21-31. PubMed ID: 17536872
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Once-weekly azithromycin in cystic fibrosis with chronic Pseudomonas aeruginosa infection.
    Steinkamp G; Schmitt-Grohe S; Döring G; Staab D; Pfründer D; Beck G; Schubert R; Zielen S
    Respir Med; 2008 Nov; 102(11):1643-53. PubMed ID: 18701270
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The use of macrolide antibiotics in patients with cystic fibrosis.
    Saiman L
    Curr Opin Pulm Med; 2004 Nov; 10(6):515-23. PubMed ID: 15510060
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A phase 2 study of aztreonam lysine for inhalation to treat patients with cystic fibrosis and Pseudomonas aeruginosa infection.
    Retsch-Bogart GZ; Burns JL; Otto KL; Liou TG; McCoy K; Oermann C; Gibson RL;
    Pediatr Pulmonol; 2008 Jan; 43(1):47-58. PubMed ID: 18041081
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Azithromycin for Early Pseudomonas Infection in Cystic Fibrosis. The OPTIMIZE Randomized Trial.
    Mayer-Hamblett N; Retsch-Bogart G; Kloster M; Accurso F; Rosenfeld M; Albers G; Black P; Brown P; Cairns A; Davis SD; Graff GR; Kerby GS; Orenstein D; Buckingham R; Ramsey BW;
    Am J Respir Crit Care Med; 2018 Nov; 198(9):1177-1187. PubMed ID: 29890086
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Improved lung function and body mass index associated with long-term use of Macrolide antibiotics.
    Pirzada OM; McGaw J; Taylor CJ; Everard ML
    J Cyst Fibros; 2003 Jun; 2(2):69-71. PubMed ID: 15463852
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Intermittent administration of inhaled tobramycin in patients with cystic fibrosis. Cystic Fibrosis Inhaled Tobramycin Study Group.
    Ramsey BW; Pepe MS; Quan JM; Otto KL; Montgomery AB; Williams-Warren J; Vasiljev-K M; Borowitz D; Bowman CM; Marshall BC; Marshall S; Smith AL
    N Engl J Med; 1999 Jan; 340(1):23-30. PubMed ID: 9878641
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Controlled trial of inhaled budesonide in patients with cystic fibrosis and chronic bronchopulmonary Psuedomonas aeruginosa infection.
    Bisgaard H; Pedersen SS; Nielsen KG; Skov M; Laursen EM; Kronborg G; Reimert CM; Høiby N; Koch C
    Am J Respir Crit Care Med; 1997 Oct; 156(4 Pt 1):1190-6. PubMed ID: 9351621
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Azithromycin for improving pulmonary function in cystic fibrosis.
    Carr RR; Nahata MC
    Ann Pharmacother; 2004 Sep; 38(9):1520-4. PubMed ID: 15213312
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Azithromycin for prevention of exacerbations in non-cystic fibrosis bronchiectasis (EMBRACE): a randomised, double-blind, placebo-controlled trial.
    Wong C; Jayaram L; Karalus N; Eaton T; Tong C; Hockey H; Milne D; Fergusson W; Tuffery C; Sexton P; Storey L; Ashton T
    Lancet; 2012 Aug; 380(9842):660-7. PubMed ID: 22901887
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A phase 3, multi-center, multinational, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of levofloxacin inhalation solution (APT-1026) in stable cystic fibrosis patients.
    Flume PA; VanDevanter DR; Morgan EE; Dudley MN; Loutit JS; Bell SC; Kerem E; Fischer R; Smyth AR; Aaron SD; Conrad D; Geller DE; Elborn JS
    J Cyst Fibros; 2016 Jul; 15(4):495-502. PubMed ID: 26852040
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Long-term daily high and low doses of azithromycin in children with cystic fibrosis: a randomized controlled trial.
    Kabra SK; Pawaiya R; Lodha R; Kapil A; Kabra M; Vani AS; Agarwal G; Shastri SS
    J Cyst Fibros; 2010 Jan; 9(1):17-23. PubMed ID: 19818694
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Maintenance azithromycin treatment in pediatric patients with cystic fibrosis: long-term outcomes related to macrolide resistance and pulmonary function.
    Tramper-Stranders GA; Wolfs TF; Fleer A; Kimpen JL; van der Ent CK
    Pediatr Infect Dis J; 2007 Jan; 26(1):8-12. PubMed ID: 17195698
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Macrolide antibiotics for cystic fibrosis.
    Southern KW; Barker PM; Solis-Moya A; Patel L
    Cochrane Database Syst Rev; 2011 Dec; (12):CD002203. PubMed ID: 22161368
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 36.